Optimizing Early-Stage NSCLC Management: A Multidisciplinary Perspective - Episode 13
Expert Insights and Best Practices in the Diagnosis of Unresectable Early-Stage NSCLC
Panelists discuss how the diagnostic workup for unresectable stage III non–small cell lung cancer (NSCLC) requires comprehensive staging including imaging studies (PET-CT, brain MRI), tissue sampling through bronchoscopy or endobronchial ultrasound (EBUS), molecular and biomarker testing, and multidisciplinary evaluation to guide optimal treatment planning.
Video content above is prompted by the following:
Diagnostic Workup for Unresectable Stage III NSCLC
Importance of Proper Staging
Accurate staging for NSCLC is critical as it:
- Determines treatment approach and prognosis
- Identifies appropriate candidates for curative-intent treatment
- Prevents futile surgery in patients with mediastinal involvement
- Guides selection of multimodality therapy options
Initial Evaluation
- Thorough History and Physical Examination
- Assess performance status (ECOG/KPS)
- Evaluate comorbidities affecting treatment tolerance
- Document smoking history and occupational exposures
- Laboratory Studies
- Complete blood count
- Comprehensive metabolic panel
- Pulmonary function tests (especially if considering surgery or radiation)
Imaging Studies
- Chest CT with Contrast
- High-resolution imaging of primary tumor and mediastinum
- Assessment of T stage and nodal involvement
- PET-CT Scan
- Standard for detecting distant metastases
- Improved sensitivity for identifying involved lymph nodes
- Essential for identifying occult metastatic disease
- Should cover from base of skull to mid thighs
- Brain MRI With Contrast
- Mandatory for all patients with stage III disease
- Up to 20% of NSCLC patients have brain metastases at diagnosis
Tissue Diagnosis and Molecular Assessment
- Core Needle Biopsy/Bronchoscopy
- Obtain adequate tissue for histologic confirmation
- Essential for molecular and immunohistochemical analysis
- Molecular Testing (required for all nonsquamous NSCLC)
- EGFR, ALK, ROS1, BRAF mutations
- NTRK gene fusions
- Consider broader next-generation sequencing panel
- PD-L1 Testing
- Mandatory for all NSCLC patients
- Guides immunotherapy decisions
Mediastinal Staging
- Invasive Mediastinal Staging (critical for stage III disease)
- Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
- Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
- Mediastinoscopy when EBUS/EUS is negative, but suspicion remains high
- Indications for Invasive Mediastinal Assessment
- Clinical N1-3 disease
- Central tumors
- Tumors >3 cm (especially adenocarcinoma)
- PET-positive mediastinal nodes
Additional Considerations
- Multidisciplinary Tumor Board Review
- Essential for optimal treatment planning
- Should include thoracic surgery, radiation oncology, medical oncology, pathology, and radiology
- Cardiopulmonary Assessment
- Comprehensive evaluation for patients being considered for multimodality treatment
- Assessment of radiation field overlap with critical cardiac structures
- Nutritional Evaluation
- Essential for patients likely to receive concurrent chemoradiation
Unresectable Stage III Determination Criteria
Stage III NSCLC is typically considered unresectable with:
- T4 lesions with involvement of heart, great vessels, trachea, carina, esophagus, vertebral body
- Extensive mediastinal involvement (N2/N3)
- Contralateral hilar or supraclavicular nodal involvement
- Malignant pleural/pericardial effusion
- Poor performance status or medical inoperability
Related Content:
